| Name | Title | Contact Details |
|---|
Clinical Innovations develops, manufactures and markets state-of-the-art medical devices that improve healthcare outcomes for clinicians and their patients worldwide. With particular emphasis on healthcare solutions for women and their infants, Clinical Innovations employs high quality standards in every aspect of business to make advancements in technology and bring innovative ideas to life.
Boston Microfluidics (BMF) is dedicated to connecting people to their health by increasing access to diagnostic testing for all people. Our technology is a unique combination of elegant sample processing solutions with an intuitive user interface. We strive to streamline current testing systems with devices that perform complex sample processing steps without the need for trained professionals or specialized laboratory equipment. We also seek to simplify diagnostic tests so that they can be used efficiently at the point of care, or even be available for direct sale to consumers. Above all, BMF works to help provide patients with the information they need to make choices about their health.
Lifemasters Supported Selfcare is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Lifemasters Supported Selfcare is based in South San Francisco, CA. You can find more information on Lifemasters Supported Selfcare at www.lifemasters.net
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.
Milliman Care Guidelines is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.